

BIOCON GROUP

FACT SHEET

March - 2022

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q4'FY 22	Q4'FY 21	Variance %
<u>INCOME</u>			
Generics	717	570	26%
Biosimilars	982	664	48%
Novel Biologics	12	11	17%
Research services	758	659	15%
Inter-segment	(61)	(61)	0%
Revenue from operations #	2,409	1,842	31%
Other income	67	205	-67%
TOTAL REVENUE	2,476	2,048	21%
<u>EXPENDITURE</u>			
Material & Power costs	911	647	41%
Staff costs	428	414	3%
Research & Development expenses*	191	127	50%
Other expenses	288	218	32%
Manufacturing, staff & other expenses	1,817	1,406	29%
EBITDA	659	641	3%
Interest & Finance charges	11	34	-69%
Depreciation & Amortisation	212	184	15%
Share of loss / (profit) in JV / Associate, net	53	70	100%
PBT BEFORE EXCEPTIONAL ITEM	384	353	9%
Exceptional item	(41)	13	-
PBT	343	366	-6%
Taxes	76	60	26%
Taxes on exceptional item	(17)	10	-276%
NET PROFIT BEFORE MINORITY INTEREST	284	296	-4%
Minority interest	46	36	25%
Minority interest on exceptional item	(0)	7	-
NET PROFIT FOR THE PERIOD	239	253	-6%
EPS Rs.	2.0	2.1	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	262	257	2%
Exceptional item, net of taxes	(24)	(4)	526%
NET PROFIT FOR THE PERIOD	239	253	-6%
<i># Licensing Income</i>	9	8	
<i>* Gross Research & Development expenses</i>	232	136	

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT

(Rs. Crores)

Particulars	Q4' FY 22	Q3' FY 22	Variance %
INCOME			
Generics	717	607	18%
Biosimilars	982	981	0%
Novel Biologics	12	16	-21%
Research services	758	641	18%
Inter-segment	(61)	(72)	-15%
Revenue from operations #	2,409	2,174	11%
Other income	67	48	39%
TOTAL REVENUE	2,476	2,223	11%
EXPENDITURE			
Material & Power costs	911	798	14%
Staff costs	428	450	-5%
Research & Development expenses*	191	138	38%
Other expenses	288	300	-4%
Manufacturing, staff & other expenses	1,817	1,686	8%
EBITDA	659	537	23%
Interest & Finance charges	11	15	-29%
Depreciation & Amortisation	212	206	3%
Share of loss / (profit) in JV / Associate, net	53	47	100%
PBT BEFORE EXCEPTIONAL ITEM	384	269	43%
Exceptional item, Net	(41)	-	-100%
PBT	343	269	27%
Taxes	76	49	53%
Taxes on exceptional item	(17)	-	0%
NET PROFIT BEFORE MINORITY INTEREST	284	220	29%
Minority interest	46	33	40%
Minority interest on exceptional item	(0)	-	-
NET PROFIT FOR THE PERIOD	239	187	28%
EPS Rs.	2.0	1.6	
NET PROFIT BEFORE EXCEPTIONAL ITEM	262	187	40%
Exceptional item, net of taxes	(24)	-	
NET PROFIT FOR THE PERIOD	239	187	28%
# Licensing Income	9	17	
* Gross Research & Development expenses	232	178	

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	FY 22	FY 21	Variance %
INCOME			
Generics	2,341	2,363	-1%
Biosimilars	3,464	2,800	24%
Novel Biologics	51	11	386%
Research services	2,604	2,184	19%
Inter-segment	(276)	(215)	29%
Revenue from operations #	8,184	7,143	15%
Other income	213	255	-16%
TOTAL REVENUE	8,397	7,398	14%
EXPENDITURE			
Material & Power costs	3,035	2,514	21%
Staff costs	1,710	1,566	9%
Research & Development expenses*	595	553	8%
Other expenses	874	858	2%
Manufacturing, staff & other expenses	6,214	5,490	13%
EBITDA	2,183	1,907	14%
Interest & Finance charges	68	58	17%
Depreciation & Amortisation	814	715	14%
Share of loss / (profit) in JV / Associate, net	207	79	100%
PBT BEFORE EXCEPTIONAL ITEM	1,094	1,055	4%
Exceptional item, Net	(111)	13	-
PBT	983	1,068	-8%
Taxes	241	212	14%
Taxes on exceptional item	(29)	10	-404%
NET PROFIT BEFORE MINORITY INTEREST	772	846	-9%
Minority interest	132	99	33%
Minority interest on exceptional item	(8)	7	-
NET PROFIT FOR THE PERIOD	648	740	-12%
EPS Rs.	5.4	6.2	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	722	744	-3%
Exceptional item, net of taxes	(74)	(4)	
NET PROFIT FOR THE PERIOD	648	740	-12%
# Licensing Income	49	40	
* Gross Research & Development expenses	711	627	

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET

(Rs Crores)

Particulars	March 31, 2022	March 31, 2021
ASSETS		
Non-current assets		
(a) Property, plant and equipment	5,677	5,557
(b) Capital work-in-progress	3,420	2,254
(c) Right-of-use assets	267	153
(d) Goodwill	26	26
(e) Other intangible assets	599	627
(f) Intangible assets under development	690	547
(g) Investment in associates and a joint venture	8	180
(h) Financial assets		
Investments	362	564
Derivative assets	147	66
Other financial assets	45	201
(i) Income tax asset, net	314	265
(j) Deferred tax asset, net	293	308
(k) Other non-current assets	163	176
Non-current assets	12,012	10,922
Current assets		
(a) Inventories	2,298	1,867
(b) Financial assets		
Investments	1,218	1,209
Trade receivables	2,058	1,503
Cash and cash equivalents	663	953
Other bank balances	1,085	1,062
Derivative assets	122	83
Loans and advances	67	-
Other financial assets	451	507
(c) Other current assets	421	364
(c) Assets held for sale	-	52
Current assets	8,382	7,600
TOTAL - ASSETS	20,394	18,522
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	600	600
(b) Other equity	7,832	7,027
Equity attributable to owners of the Company	8,433	7,627
Non-controlling interests	1,038	881
Total Equity	9,471	8,508
Non-current liabilities		
(a) Financial liabilities		
Borrowings	3,999	2,962
Lease liabilities	222	114
Derivative liabilities	14	62
Other financial liabilities	1,503	1,503
(b) Provisions	92	106
(c) Deferred tax liability, net	52	32
(d) Other non-current liabilities	1,215	1,025
Non-current liabilities	7,096	5,805
Current liabilities		
(a) Financial liabilities		
Borrowings	906	1,397
Lease liabilities	21	8
Trade payables	1,609	1,514
Derivative liabilities	12	26
Other financial liabilities	363	382
(b) Provisions	131	109
(c) Income tax liability, net	162	152
(d) Other current liabilities	625	581
(e) Liabilities classified as held for sale	-	40
Current liabilities	3,827	4,210
TOTAL - EQUITY AND LIABILITIES	20,394	18,522